Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH (Coli-NASH)
Sponsor: University Hospital, Toulouse
This observational or N/A phase trial investigates Non-alcoholic Fatty Liver Disease and is currently completed. University Hospital, Toulouse leads this study, which shows 12 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 7 earlier versions
-
Sep 2018 — Nov 2020 [monthly]
Completed
-
Jun 2018 — Sep 2018 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Completed NA
Status: Recruiting → Completed
-
Aug 2017 — Mar 2018 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital, Toulouse
For direct contact, visit the study record on ClinicalTrials.gov .